纳米载体以及/或者纳米药物,作为立异型的药物制剂的紧张方式,自己具备配合的器官靶向以及循环性子,经由集成立异,实现多种药物的共负载、靶向递送以及可控释放。在泛滥临床疾病中,恶性肿瘤病理微情景重大、治疗难度高,是纳米药物钻研的紧张内容。自1995年第一款纳米药物—阿霉素脂质体Doxil被FDA称许以来,进入临床的传统抗肿瘤纳米药物概况履历了两个代际的睁开。第一代纳米药物主要搜罗Doxil等以脂质体为主要载体的纳米药物,载带小份子化疗药物,经由肿瘤血管自己高渗透以及滞留效应(Enhanced Penetration and Retention, EPR)使纳米药物自动富集到肿瘤机关,飞腾化药的毒副熏染;第二代纳米药物Abraxane以及Genexol-PM等主要运用胶束、白卵白等生物相容性好的份子作为质料分解纳米载体,载带的药物规范除了搜罗化疗药物之外,尚有核酸、多肽以及卵白类药物,同时对于载体概况妨碍PEG修饰缩短血液循环光阴,用于肿瘤的基因治疗、免疫治疗以及散漫治疗等。还搜罗ThermoDox、BIND-014等在纳米载体中引入自动寻靶以及情景照应性份子单元,以实现药物的自动靶向以及可控释放,以及一些有机纳米质料为代表的此外运用。而近多少年崛起的第三代纳米药物是智能化的时期,咱们演绎综合地称之为智能纳米机械。狭义上说搜罗了临床前钻研中的外泌体(exosome)、细胞膜、细菌外膜囊泡、微颗粒等做作质料,以及DNA框架自组装、DNA折纸等精准可控载体分解技术制备的纳米机械药物[3-8],以实现多种致病因素的共消除了以及疾病微情景的实用调控。这些具有情景照应性、病灶自动识别以及特异性照应特色的纳米药物已经初具智能纳米机械的雏形,不光能改善传统纳米药物的疗效与清静性失调的挑战,同时也为搜罗mRNA药物以及疫苗、基因编纂、干细胞治疗以及特色化肿瘤疫苗等新兴技术的体内运用奠基了普遍的迷信以及技术根基,具备较强的临床运用价钱以及远景。
[2] Zhou MG, Wang HD, Zeng XY, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990—2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019, 394(10204): 1145—1158.
[3] Tian YH, Li SP, Song J, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials, 2014, 35(7): 2383—2390.
[4] Hu CM, Fang RH, Wang KC, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature, 2015, 526(7571): 118—121.
[5] Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nature Reviews Microbiology, 2015, 13(10): 605—619.
[6] Liang QL, Bie NN, Yong TY, et al. The softness of tumour-cell-derived microparticles regulates their drug-delivery efficiency. Nature Biomedical Engineering, 2019, 3(9): 729—740.
[7] Wang C, Piao JF, Li YJ, et al. Construction of liposomes mimicking cell membrane structure through frame-guided assembly. Angewandte Chemie International Edition, 2020, 59(35): 15176—15180.
[8] Li SP, Jiang Q, Liu SL, et al. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nature Biotechnology, 2018, 36(3): 258—264.
[9] Lee I, Razaghi R, Gilpatrick T, et al. Simultaneous profiling of chromatin accessibility and methylation on human cell lines with nanopore sequencing. Nature Methods, 2020, 17(12): 1191—1199.
[10] Xianyu YL, Wu J, Chen YP, et al. Controllable assembly of enzymes for multiplexed Lab-on-a-Chip bioassays with a tunable detection range. Angewandte Chemie International Edition, 2018, 57(25): 7503—7507.
[11] Yang MZ, Zhang W, Yang JC, et al. Skiving stacked sheets of paper into test paper for rapid and multiplexed assay. Science Advances, 2017, 3(12), eaao4862.
[12] Lu Y, Aimetti AA, Langer R, et al. Bioresponsive materials. Nature Reviews Materials, 2016, 2(1): 16075.
[13] Zhang WJ, Hu XL, Shen Q, et al. Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy. Nature Co妹妹unications, 2019, 10(1): 1704.
[14] Zhang LJ, Qi YQ, Min H, et al. Cooperatively responsive peptide nanotherapeutic that regulates angiopoietin receptor Tie2 activity in tumor microenvironment to prevent breast tumor relapse after chemotherapy. Acs Nano, 2019, 13(5): 5091—5102.
[15] Korin N, Kanapathipillai M, Matthews BD, et al. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science, 2012, 337(6095): 738—742.
[16] Liang MM, Fan KL, Zhou M, et al. H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111(41): 14900—14905.
[17] Yuan Y, Du C, Sun CJ, et al. Chaperonin-GroEL as a smart hydrophobic drug delivery and tumor targeting molecular machine for tumor therapy. Nano Letters, 2018, 18(2): 921—928.
[18] Zipkin M. Big pharma buys into exosomes for drug delivery. Nature Biotechnology, 2020, 38(11): 1226—1228.
[19] Felfoul O, Moha妹妹adi M, Taherkhani S, et al. Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions. Nature Nanotechnology, 2016, 11(11): 941—947.
[20] Eskandari SK, Sulkaj I, Melo MB, et al. Regulatory T cells engineered with TCR signaling-responsive IL-2 nanogels suppress alloi妹妹unity in sites of antigen encounter. Science Translational Medicine, 2020, 12(569): eaaw4744.
[21] Tang L, Zheng YR, Melo MB, et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nature Biotechnology, 2018, 36(8): 707—716.